MedTrace Logo

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

NCT02264210 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2024-09-25

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well icotinib works in treating patients with completely resected stage IB NSCLC harboring EGFR mutation.

Conditions

  • Lung Neoplasms
  • Squamous Cell Lung Cancer
  • Adenocarcinoma of the Lung
  • Adenosquamous Cell Lung Cancer
  • Large Cell Lung Cancer
  • Bronchial Neoplasms
  • Stage IB Non-small Cell Lung Cancer

Interventions

DRUG

Icotinib

Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Si-Yu Wang, MD · Guangdong Province Association Study of Thoracic Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2020-12-31
Completion
2022-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02264210 on ClinicalTrials.gov